Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27686922 | 0.82 | OPRM1 (0.52) | LMNAOPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL10655338 | 0.78 | HTT (0.41) | ATMHTTOPRL1OPRM1OPRD1 | |
| SCHEMBL23491506 | 0.77 | CHRNB2 (0.53) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL4242365 | 0.77 | OPRL1 (0.56) | HTTKMT2AOPRL1OPRM1OPRD1 | |
| SCHEMBL153569 | 0.72 | OPRL1 (0.59) | OPRL1OPRM1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL3736894 | 0.70 | TMEM97 (0.44) | NPSR1MEN1KMT2AOPRL1SMN1; SMN2 | |
| SCHEMBL1205908 | 0.69 | OPRM1 (0.61) | MAPTKMT2AOPRL1OPRM1OPRD1 | |
| SCHEMBL21077926 | 0.69 | OPRL1 (0.58) | OPRL1OPRM1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL4294175 | 0.68 | CHRNB2 (0.77) | CHRNB2CHRNB4CHRNA3CHRNA7CHRNA4 | |
| SCHEMBL5759075 | 0.68 | KDM4E (0.48) | KMT2AOPRL1OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9993529-B2 | Stable formulations of a hyaluronan-degrading enzyme | HALOZYME, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| EP-2720712-B1 | STABLE FORMULATIONS OF A HYALURONAN-DEGRADING ENZYME | HALOZYME INC (US) | 2016-03-02 | — | — | EP | disclosed |
| US-20130022592-A1 | Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme | HALOZYME THERAPEUTICS, INC. | 2013-01-24 | — | — | US | disclosed |
| US-20130022588-A1 | Stable formulations of a hyaluronan-degrading enzyme related applications | HALOZYME THERAPEUTICS, INC. | 2013-01-24 | — | — | US | disclosed |
| US-20130011378-A1 | Stable formulations of a hyaluronan-degrading enzyme | HALOZYME THERAPEUTICS, INC. | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130022588-A1 | Stable formulations of a hyaluronan-degrading enzyme related applications | IDE, MMP20, IDUA | CHRNB2 4515/4885CHRNB4 4557/4885CHRNA3 4653/4885 |
| US-20130011378-A1 | Stable formulations of a hyaluronan-degrading enzyme | IDE, IDUA, MMP20 | CHRNB2 4513/4885CHRNB4 4524/4885CHRNA3 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.